10 Evidence-Informed Habits to Support Long-Term GLP-1 Treatment

Building a Sustainable Approach to GLP-1 Treatment

GLP-1–based and related incretin therapies have changed the treatment of obesity and weight-related disease. For many individuals, these medications can meaningfully reduce appetite, food intake, and body weight while improving certain cardiometabolic outcomes.

Medication, however, is only one component of long-term health.

As appetite and weight change, patients may need to pay closer attention to nutrition quality, protein and micronutrient intake, muscle preservation, physical activity, gastrointestinal tolerance, sleep, treatment adherence, and other health behaviors.

Current expert guidance emphasizes combining GLP-1 treatment with individualized nutrition and lifestyle support rather than relying on medication alone. 

The goal is not to achieve “maximum” weight loss at any cost. It is to support safe, sustainable treatment while protecting overall health and physical function.

1. Follow the Prescribed Treatment Plan

GLP-1–based medications should be used according to the prescribing clinician’s instructions.

Do not independently:

• increase or decrease the dose
• shorten or extend dosing intervals
• skip doses strategically to change weight-loss speed
• combine medications
• alter treatment because weight loss slows

Questions about medication response, tolerability, dose escalation, side effects, or treatment goals belong with the licensed prescribing clinician.

Consistency is important, but so is individualized medical management. A person experiencing significant side effects or difficulty maintaining adequate nutrition should not simply “push through” treatment without contacting the care team.

2. Prioritize Nutrition Quality When Appetite Decreases

Reduced appetite can make it easier to eat less—but eating less does not automatically mean eating well.

When total food intake declines substantially, smaller meals need to provide adequate nutrition.

The 2025 multisociety GLP-1 advisory identifies nutritional adequacy as a major treatment priority, including attention to protein, micronutrients, gastrointestinal symptoms, dietary quality, and individualized nutritional needs. 

Useful priorities may include:

• protein-rich foods
• vegetables and fruit
• whole grains and legumes as tolerated
• healthy fats
• adequate vitamins and minerals
• appropriate fiber
• sufficient fluids

There is no single “GLP-1 diet” that is appropriate for everyone.

3. Pay Attention to Protein and Muscle Preservation

Weight reduction includes loss of fat mass, but some lean tissue can also be lost.

That makes muscle preservation an important part of comprehensive obesity treatment—not simply an aesthetic concern.

Current reviews emphasize adequate high-quality protein, micronutrient intake, and physical activity, particularly resistance training, as strategies that may help minimize loss of muscle mass and function during treatment with incretin-based obesity medications. 

Individual protein requirements vary based on factors such as:

• age
• body size
• physical activity
• kidney function
• health conditions
• total energy intake

Universal protein prescriptions should therefore be avoided.

4. Include Resistance Training and Regular Movement

Exercise should not be framed as a way to “make GLP-1 work better” or “reignite metabolism.”

It has its own important health benefits.

Resistance exercise can support:

• muscle strength
• physical function
• preservation of lean mass
• bone health
• mobility
• long-term independence

Aerobic activity supports cardiovascular fitness and broader metabolic health.

A randomized trial involving liraglutide found that combining structured exercise with pharmacotherapy produced favorable weight-maintenance and body-composition outcomes compared with several other treatment strategies.  Follow-up data also suggested better weight maintenance after treatment ended among participants who had incorporated supervised exercise. 

Those findings should not be generalized to every GLP-1 medication or exercise plan, but they reinforce the value of physical activity as part of comprehensive obesity care.

5. Manage Gastrointestinal Symptoms Early

Nausea, vomiting, constipation, diarrhea, early fullness, and other gastrointestinal symptoms can interfere with hydration and nutritional intake.

Patients should not assume that severe or persistent symptoms are simply the price of successful treatment.

Practical strategies may include:

• smaller meals
• slower eating
• stopping when comfortably full
• choosing foods that are better tolerated
• adequate hydration
• adjusting fiber gradually when appropriate

Persistent vomiting, inability to maintain fluids, severe abdominal symptoms, or other concerning adverse effects warrant communication with the prescribing healthcare professional.

6. Maintain Adequate Hydration

Hydration is important during GLP-1 treatment, particularly when appetite is reduced or gastrointestinal symptoms affect fluid intake.

Water does not need to be described as “amplifying GLP-1 activity.”

Its value is simpler and better established: adequate hydration supports normal physiological function and can become especially important when nausea, vomiting, diarrhea, constipation, or reduced food intake are present.

Fluid requirements vary. Individuals with kidney, heart, endocrine, or other medical conditions may require individualized guidance.

7. Protect Sleep and Recovery

Sleep is an important component of overall health, appetite regulation, emotional well-being, physical activity, and treatment adherence.

Rather than claiming that sleep “improves GLP-1 response,” it is more accurate to treat sleep as part of a comprehensive health strategy.

The multisociety GLP-1 advisory specifically includes sleep, mental stress, physical activity, substance use, and social connection among lifestyle factors that should be assessed during obesity treatment. 

A consistent sleep schedule, adequate opportunity for sleep, and evaluation of possible sleep disorders can support overall health independent of any direct effect on the medication.

8. Monitor Progress Beyond the Scale

Body weight matters, but it is not the only meaningful outcome.

Depending on the individual, progress may also include:

• improved waist circumference
• greater strength
• improved mobility
• better physical endurance
• improved blood pressure
• improved glucose measures
• better dietary quality
• improved sleep
• reduced food preoccupation
• increased confidence managing treatment

Periods of slower weight loss or weight maintenance do not automatically indicate failure.

Treatment goals should be individualized and periodically reviewed with the healthcare team.

9. Use Education and Support Rather Than Going It Alone

GLP-1 treatment can create practical questions that extend beyond medication dosing.

Patients may need help understanding:

• nutrition when appetite is low
• gastrointestinal tolerance
• self-injection
• physical activity
• weight plateaus
• meal planning
• emotional eating
• expectations
• when to contact the prescribing clinician

The multisociety advisory specifically identifies registered dietitian counseling, group-based care, telehealth, digital platforms, and other supportive strategies as potential components of comprehensive GLP-1 obesity treatment. 

Support should complement—not replace—licensed medical care.

10. Think of Obesity Treatment as Long-Term Care

One of the most important expectations to establish is that obesity is generally a chronic disease.

GLP-1 therapy should not automatically be viewed as a short-term intervention that permanently resets metabolism.

In the STEP 1 extension, participants who stopped semaglutide regained approximately two-thirds of their prior weight loss during the following year, and several cardiometabolic improvements moved back toward baseline. 

This does not mean every individual must remain on the same medication indefinitely. It means decisions about continuation, adjustment, transition, or discontinuation should be made deliberately with the prescribing clinician.

Lifestyle habits remain valuable whether treatment continues, changes, or eventually stops—but they should not be promoted as a guarantee against weight regain.

What Long-Term GLP-1 Support Should Not Promise

Be cautious of claims that a particular diet, supplement, exercise plan, or wellness program will:

• “maximize” GLP-1 results
• permanently reset metabolism
• prevent all weight regain
• guarantee continued weight loss
• naturally reproduce medication effects
• make GLP-1 therapy more effective by “boosting” the hormone
• eliminate the need for ongoing medical management

Those claims exceed what the evidence currently supports.

A stronger approach is individualized care built around appropriate medication management, adequate nutrition, physical activity, muscle preservation, symptom management, education, and realistic long-term expectations.

How My NuEra Rx Supports the Treatment Journey

My NuEra Rx emphasizes education, informed decision-making, and ongoing support throughout the wellness and weight-management experience.

Patients using prescribed GLP-1–based or related therapies may benefit from support around nutrition, treatment expectations, self-administration, lifestyle habits, questions for the prescribing clinician, and recognizing when additional medical evaluation is appropriate.

Medication selection, prescribing, dose adjustments, adverse-effect management, and individualized medical decisions remain under the direction of appropriately licensed healthcare professionals.

The goal is not to promise a perfect or uninterrupted weight-loss journey. It is to help patients remain informed, engaged, and prepared as their treatment needs evolve.

Final Thoughts

Long-term success with GLP-1 treatment should not be defined solely by how quickly the number on the scale changes.

A more complete definition includes maintaining nutritional adequacy, preserving strength and function, staying physically active, managing side effects, following the prescribed treatment plan, maintaining realistic expectations, and remaining connected with the healthcare team.

GLP-1 medications can be powerful tools. Their role is strengthened—not replaced—by thoughtful nutrition, physical activity, education, and comprehensive long-term care.

⸻

References

1. Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory. American Journal of Clinical Nutrition. 2025;122(1):344–367. PubMed 
2. Lundgren JR, Janus C, Jensen SBK, et al. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. New England Journal of Medicine. 2021;384(18):1719–1730. PubMed 
3. Jensen SBK, et al. Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment. 2024. PubMed 
4. Mechanick JI, Butsch WS, Christensen SM, et al. Strategies for Minimizing Muscle Loss During Use of Incretin-Mimetic Drugs for Treatment of Obesity. Obesity Reviews. 2025;26(1):e13841. PubMed 
5. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022. PubMed 

About the Author

Ykama Wilson, MSN, RN is a registered nurse and healthcare leader with more than 25 years of experience spanning clinical nursing, patient and healthcare professional education, and the pharmaceutical and medical device industries. She is the Founder & Owner of My NuEra Rx, where her work focuses on education, informed decision-making, patient support, and modern wellness.

Learn more about Ykama Wilson:
https://mynuerarx.com/ykama-wilson/

This article is for educational purposes only and is not intended to provide individualized medical advice, diagnosis, or treatment. Medication selection, dosing, treatment changes, and medical decisions should be made in consultation with an appropriately licensed healthcare professional.